Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Q4 2025 Management View CEO Paul LaViolette stated that Pulse Biosciences is “creating a pulsed field ablation platform to completely shift how physicians treat disease” by advancing nanosecond pulsed ...

As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...

The introduction of Joint Clinical Assessment JCA marks one of the most significant regulatory and market access changes in the European pharmaceutical landscape in decades. Established under the ...

Vantage Clinical Partners provides assessment, program development, and operational optimization services across key ...

Core Economic Terms of $6.0 Million Financing Remain Unchanged Jupiter Neurosciences, Inc. (NASDAQ:JUNS)That alignment ...

Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...

Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago The ...